An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Tesseract Health Appoints Dr. Michael McConnell as Head of Cardiovascular and Digital Health
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Tesseract Health has appointed Michael McConnell, MD, MSEE, as Head of Cardiovascular and Digital Health, strengthening its leadership under CEO Vicky Demas. Dr. McConnell brings expertise from Google Health and aims to guide the development of cardiovascular health products using Tesseract's non-invasive technology. The company is focused on democratizing health screening and aims to innovate ocular health diagnostics. Tesseract is part of 4Catalyzer, which includes companies like Butterfly Network (NYSE: BFLY), Quantum-Si (NASDAQ: QSI), and Hyperfine (NASDAQ: HYPR).
Positive
Appointment of Dr. McConnell enhances leadership and expertise.
Focus on democratizing health screening and innovative diagnostic technology.
Strong backing from 4Catalyzer, increasing potential for growth.
Negative
The Tesseract platform is not FDA cleared or available for sale, which may limit immediate market potential.
Former Google Health Executive to Expand Cardiovascular Strategy for Ocular Health Technology Company
GUILFORD, Conn.--(BUSINESS WIRE)--
Tesseract Health, a health technology company developing a portable, non-invasive platform to detect health conditions through the eyes, proudly announces the appointment of Michael McConnell, MD, MSEE, as Tesseract’s Head of Cardiovascular and Digital Health. This key role completes Tesseract’s leadership team and coincides with a series of critical, strategic hires under the helm of CEO Vicky Demas, PhD.
Dr. McConnell was brought on to leverage Tesseract’s technology to guide the expansion of its cardiovascular strategy. In this role, he is poised to lead and champion the design, planning, development and clinical research for cardiovascular health products. Dr. McConnell trained at MIT, Stanford, and Harvard and directed programs in cardiovascular imaging, prevention, and digital health at Stanford Medicine, and then Google, as the senior clinical lead at Google Health/Fitbit.
“I’m very excited to join Dr. Demas and the Tesseract Health leadership team to advance our mission to democratize point-of-care screening and monitoring of important health conditions,” said Dr. McConnell. “My academic and industry career has focused on leveraging technology for early disease detection and prevention, and demonstrated how the eye provides a direct window to see the impact of diabetes, high blood pressure, and risk of heart attack and stroke. I aim to bring my expertise in imaging, prevention, and digital health to develop innovative, new ocular health biomarkers and products to help people around the world live healthier lives.”
Tesseract aims to create a new standard in diagnostics that will bridge imaging technology and laboratory medicine, leveraging technology and AI to detect health conditions through the eyes. To achieve this mission, Tesseract has recruited a diverse team of healthcare, medical device, and technology experts – all with the goal of redesigning the future of healthcare through the deployment of connected, smart devices.
“I am honored that Dr. McConnell has joined our incredibly talented team to launch an end-to-end solution that enables health screening outside of specialists’ offices,” states Dr. Demas. “I am confident that our pipeline of non-invasive health products will change the way we address systemic disease moving forward.”
About Tesseract HealthTM
Tesseract Health is a venture-backed, technology company developing a portable, non-invasive platform to detect health conditions through the eyes, and is part of 4Catalyzer, a medical technology accelerator founded by Dr. Jonathan Rothberg which has launched Butterfly Network (NYSE: BFLY), Quantum-Si (NASDAQ: QSI), Hyperfine and Liminal Sciences (NASDAQ: HYPR), Detect, AI Therapeutics, Tesseract, and Protein Evolution. All of the 4Catalyzer companies are transforming 21st century medicine and improving our planet by solving today’s most challenging problems across life science research tools, medical devices, therapeutics and the environment. To learn more, visit: TesseractHealth.com.
The Tesseract platform is not FDA cleared or available for sale.
